ASAC: Aspirin Fails as Adjuvant for Colorectal Liver Mets (50% Develop Them)

Biopharma developers tracking adjuvant colorectal cancer should read ASAC as a repurposing failure that leaves the field open for innovation. Up to half of colorectal cancer patients develop liver metastases, and recurrence after surgery remains high, so a generic agent might have addressed a large population. With aspirin showing no benefit, the unmet need shifts squarely to biomarker-defined novel agents and immunotherapies.

According to a Newswise summary published on October 2, 2026, the Scandinavian ASAC trial found no benefit from aspirin when given after curative-intent treatment for colorectal cancer liver metastases. The result is clinically important because colorectal cancer is one of the most common cancers worldwide, and up to half of patients develop liver metastases during the course of their disease. For patients whose liver lesions are amenable to surgery, often combined with local ablative treatment, these procedures remain the main potentially curative option. Yet the risk of cancer recurrence after such treatment is high, which is why investigators designed ASAC to test whether aspirin could reduce recurrence. The negative outcome closes a much-discussed low-cost repurposing pathway and reorients clinical practice toward more selective strategies.

“

According to a Newswise summary published on October 2, 2026, the Scandinavian ASAC trial found no benefit from aspirin when given after curative-intent treatment for colorectal cancer liver metastases.

The biological rationale for aspirin in this setting was never weak. Aspirin inhibits cyclooxygenase-2 (COX-2) and reduces platelet-mediated inflammatory signaling, both of which have been implicated in colorectal tumor progression and metastasis. Observational studies and secondary analyses of cardiovascular prevention trials had raised hopes that aspirin might reduce colorectal cancer incidence and death. However, those signals had not been confirmed in a randomized trial specifically focused on post-metastasectomy colorectal cancer patients. ASAC was meant to provide that prospective evidence. The Newswise release does not include sample size, follow-up duration, recurrence rates, or hazard ratios, so the magnitude and precision of the null effect cannot be assessed from this announcement alone. Still, the headline conclusion is unambiguous: no benefit.

For oncologists and health systems, the finding has immediate practical implications. It means aspirin should not be routinely prescribed after curative-intent treatment of colorectal cancer liver metastases outside of a clinical trial. This avoids exposing patients to aspirin's known bleeding risks without a corresponding recurrence-reduction benefit. The result also reinforces the broader principle that observational associations do not always translate into randomized trial benefit, particularly in adjuvant settings where recurrence biology may differ from primary prevention biology. Clinical pathways for post-metastasectomy care should continue to emphasize surveillance imaging, multidisciplinary tumor boards, and enrollment in trials of novel agents rather than off-label aspirin.

For the biopharma sector, the ASAC result is a reminder that the unmet need in high-recurrence colorectal cancer liver metastases remains substantial. A generic, inexpensive drug would have been difficult to monetize, but its failure leaves room for development of molecularly targeted therapies, immunotherapies, and biomarker-selected approaches. Future analyses of the ASAC study may explore subgroups such as patients with PIK3CA mutations or high COX-2 expression, which some prior data suggested might derive differential benefit from aspirin. If such subgroups exist, they could inform more precise adjuvant trial designs. Until such data are published in a peer-reviewed venue, the broad takeaway is negative.